BANZEL® (rufinamide) OFFERS FLEXIBLE DOSING OPTIONS
So you can tailor therapy to individual patient needs
Pediatric Dosing
Dosing starts at 10 mg/kg/day, divided into 2 equal doses.1
Increase dose by approximately 10 mg/kg increments every other day until your patient reaches therapeutic response, up to a maximum of 45 mg/kg/day or 3200 mg/day, whichever is less, divided into 2 equal doses1
Adult Dosing
Dosing starts at 400-800 mg/day, divided into 2 equal doses.1
Increase dose by 400-800 mg every other day until your patient reaches therapeutic response, up to a maximum dose of 3200 mg/day, divided into 2 equal doses1
In the pivotal trial, dosage reductions were permitted during titration if problems in tolerability were encountered.1
- Target dosage was achieved in 88% of the BANZEL-treated patients1
- The majority of these patients reached the target dose within 7 days, with the remaining patients achieving the target dose within 14 days1
- The average daily dose during the maintenance period in the pivotal trial: 1665 mg/day for all patients2
- It is not known whether doses lower than the target dose are effective
Patients taking valproate should begin BANZEL at a dose lower than 10 mg/kg per day in pediatric patients or 400 mg/day for adults.1
Multiple dosing options when adding BANZEL
BANZEL offers 2 formulations for administration1
Multiple dosing options when adding BANZEL
BANZEL offers 2 formulations for administration1
- Tablets: 200 mg and 400 mg
- Oral suspension: 40 mg/mL
- Tablets can be administered whole, as half tablets, or crushed1
- Advise patients to take BANZEL with food1
- References: 1. BANZEL® (rufinamide) prescribing information, Eisai Inc. 2. Data on file, Eisai Inc.